Nov 20, 2015 | News
John Ratliff recently retired from Quintiles as President and Chief Operating Officer. He led Quintiles’ Global Services organization with it’s clinical research, commercial, consulting, lab operations and was a member of the company’s Board of Directors. John helped...
Jun 22, 2015 | News
Phase 2a Clinical Trial of a Novel Nuclear Receptor Agonist in Alzheimer’s patients expected to initiate in 3Q2015. Read More
Jun 8, 2015 | News
T3D Therapeutics, Inc. has been selected by the Alzheimer’s Association to present pre-clinical results of T3D-959 at the upcoming Alzheimer’s Association International Conference (AAIC) in Washington, DC, July 18-23, 2015. The poster presentation will provide details...
May 18, 2015 | News
T3D Therapeutics announced the addition of three new members to its Advisory Board complementing Alzheimer’s disease and CNS expertise with pharmaceutical licensing, clinical development and business acumen; Jason Kralic Ph.D., Stuart Hobbs, Pharm.D., and Wesley...
Mar 24, 2015 | News
NIA/NIH grant support for Phase 2a clinical testing of a new, potentially disease-modifying therapy tor Alzheimer’s disease. Read More
